JGC
STRO icon

J. Goldman & Co’s Sutro Biopharma STRO Stock Holding History

J. Goldman & Co’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,323
Closed -$439K – 435
2021
Q3 		$439K Sell
2,323
-4,821
-67% -$917K 0.02% 284
2021
Q2 		$1.33M Buy
7,144
+2,252
+46% +$441K 0.05% 267
2021
Q1 		$1.11M Sell
4,892
-9,570
-66% -$2.27M 0.04% 297
2020
Q4 		$3.14M Buy
+14,462
New +$2.39M 0.16% 150

Other funds holding STRO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

J. Goldman & Co's STRO Position: Q4 2021 in Review

J. Goldman & Co sold out of Sutro Biopharma (STRO) in Q4 2021, closing a stake of 2,323 shares — an estimated $439K sold.

J. Goldman & Co first reported a position in STRO in Q4 2020 and held it in 4 quarters. The position peaked at $3.14M in Q4 2020. 117 funds tracked by Wall St. Rank hold STRO as of Q4 2021.

  • J. Goldman & Co reported no remaining Sutro Biopharma position as of Q4 2021 after selling out during the quarter.
  • J. Goldman & Co sold 2,323 Sutro Biopharma shares in Q4 2021, an estimated $439K.
  • J. Goldman & Co first reported a position in Sutro Biopharma in Q4 2020 and held it in 4 quarters.
  • J. Goldman & Co's Sutro Biopharma position peaked at $3.14M in Q4 2020.
  • 117 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2021.

Based on J. Goldman & Co's 13F filing for Q4 2021, filed 14 Feb 2022.